Lilly shares climb as next-generation obesity drug data cements market lead
Eli Lilly (LLY) shares rose 4% after the drugmaker presented compelling data for retatrutide, its next-generation obesity treatment, fueling expectations among analysts and investors that the company will extend its dominance of the…
